Loading clinical trials...
Loading clinical trials...
A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Conditions
Interventions
BMS-986036
Placebo
Locations
89
United States
Local Institution - 0087
Madison, Alabama, United States
Local Institution - 0005
Chandler, Arizona, United States
Local Institution - 0088
Phoenix, Arizona, United States
Local Institution - 0001
Phoenix, Arizona, United States
The Institute for Liver Health - Tucson
Tucson, Arizona, United States
Kindred Medical Institute for Clinical Trials
Corona, California, United States
Start Date
June 19, 2018
Primary Completion Date
September 14, 2020
Completion Date
August 17, 2021
Last Updated
September 9, 2022
NCT07417553
NCT07265544
NCT06632444
NCT04429100
NCT02815891
NCT06318169
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions